术前胚胎冷冻保存联合内镜手术(手术-辅助生殖技术混合治疗)在卵巢储备功能减退且合并子宫肌瘤或卵巢子宫内膜异位囊肿的不孕女性中的效果
回顾性队列研究分析2014至2016年间39例卵巢储备功能减退(抗苗勒管激素<1.0 ng/mL)和/或高龄(>40岁)合并子宫肌瘤和/或卵巢子宫内膜异位囊肿的不孕女性,接受术前胚胎冷冻保存联合内镜手术(手术-辅助生殖技术混合治疗)的结局。14例获得活产,24例(63.2%)种植失败或流产;活产组年龄显著低于失败组,术前冷冻胚胎数显著多于失败组。
要点
- 39例接受手术-辅助生殖技术混合治疗,14例活产,24例(63.2%)种植失败或流产。
- 活产组中位年龄40岁低于失败组41.5岁(p=0.032)。
- 活产组术前冷冻胚胎数中位5.0个多于失败组2.0个(p<0.001)。
核心结论
- 成功的手术-辅助生殖技术混合治疗需要术前有足够数量的年龄特异性冷冻胚胎、建立具有稳定妊娠结局的辅助生殖技术治疗、熟练的生殖手术以及患者和医生强烈的妊娠意愿。
研究设计与样本
- 回顾性队列研究,分析2014年至2016年间在顺天堂大学医院和杉山诊所接受手术-辅助生殖技术混合治疗的所有患者数据。
- 共39例不孕女性接受手术-辅助生殖技术混合治疗,包含86个胚胎移植周期。
- 比较混合治疗后获得活产(成功组)与种植失败或流产(失败组)的女性,评估活产的预测因素。
主要发现
- 39例中1例取卵后未获得胚胎并放弃受孕,14例分娩(成功组),24例(63.2%)种植失败或流产(失败组)。
- 成功组中位年龄40岁(四分位距38-41岁)vs 失败组41.5岁(四分位距41-42岁),p=0.032。
- 成功组血清抗苗勒管激素2.5 ng/mL(范围0.1-8.6 ng/mL)vs 失败组1.3 ng/mL(范围0.1-4.2 ng/mL),p=0.396。
- 成功组术前冷冻胚胎数5.0个(范围4.0-6.0)vs 失败组2.0个(范围1.0-3.0),p<0.001。
- 两组子宫肌瘤和子宫内膜异位症的手术所见无显著差异。
关键数值与推荐
- 纳入标准:卵巢储备功能减退(抗苗勒管激素<1.0 ng/mL)和/或高龄(>40岁),合并需手术的子宫肌瘤和/或卵巢子宫内膜异位囊肿。
- 所有女性术前接受辅助生殖技术治疗进行胚胎冷冻保存,随后进行生殖手术,术后避孕间期后行冻融胚胎移植(手术-辅助生殖技术混合治疗)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To analyze the clinical outcomes of and predictive factors for the therapeutic effect of combination treatment of preoperative embryo cryopreservation and endoscopic surgery (surgery-assisted reproductive technology [ART] hybrid therapy) in infertile women with diminished ovarian reserve (DOR) with uterine fibroids and/or ovarian endometriomas. DESIGN: Retrospective cohort study. SETTING: Data from all patients who underwent surgery-ART hybrid therapy at Juntendo University Hospital and Sugiyama Clinic between 2014 and 2016 were analyzed retrospectively. We compared women who experienced live birth (success group) and implantation failure or miscarriage (failure group) after surgery-ART hybrid therapy and evaluate the predictive factors for live birth. PATIENTS: A total of 39 infertile women underwent surgery-ART hybrid therapy with 86 embryo transfer cycles. INTERVENTIONS: All women underwent ART treatment for embryo cryopreservation preoperatively, reproductive surgery, and warmed embryo transfer after the postoperative contraceptive interval (surgery-ART hybrid therapy) for women with DOR (anti-Müllerian hormone <1.0 ng/mL) and/or advanced reproductive age (>40 years) with uterine myomas and/or ovarian endometriomas who required surgery. RESULTS: Among 39 women underwent surgery-ART hybrid therapy, 1 woman acquired no embryo after oocyte retrieval trials and abandoned efforts to conceive, 14 experienced childbirth (success group) and 24 (63.2%) experienced implantation failure or miscarriage (failure group) after surgery-ART hybrid therapy. The median patient age was 40 years (interquartile range [IQR], 38-41 years) in the success group and 41.5 years (IQR, 41-42 years) in the failure group (p = .032). The respective serum anti-Müllerian hormone levels were 2.5 ng/mL (range, 0.1-8.6 ng/mL) and 1.3 ng/mL (range, 0.1-4.2 ng/mL) (p = .396), and the respective numbers of preoperative frozen were 5.0 (range, 4.0-6.0) and 2.0 (range, 1.0-3.0) (p < .001). There were no significant differences in surgical findings of myomas and endometriosis between the 2 groups. Compared with the 24 women who experienced hybrid therapy failure, the 14 who underwent successful surgery-ART hybrid therapy were significantly younger and had a greater number of cryopreserved embryos. CONCLUSION: Successful surgery-ART hybrid therapy requires a sufficient preoperative age-specific number of frozen embryos, establishment of ART treatment with stable pregnancy outcomes and skillful reproductive surgery, and a strong desire of the patient and doctor for pregnancy.
引用
- Kuroda K, Ikemoto Y, Ochiai A, et al. Combination Treatment of Preoperative Embryo Cryopreservation and Endoscopic Surgery (Surgery-ART Hybrid Therapy) in Infertile Women with Diminished Ovarian Reserve and Uterine Myomas or Ovarian Endometriomas. J Minim Invasive Gynecol. 2019. PMID: 30794888. doi:10.1016/j.jmig.2019.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。